APPLICATION OF MITOXANTHONE HYDROCHLORIDE LIPOSOM FOR THE TREATMENT OF BREAST CANCER Russian patent published in 2023 - IPC A61K31/136 A61K47/24 A61K47/28 A61K9/127 A61P35/00 A61P35/04 

FIELD: antitumor therapy.

SUBSTANCE: use of mitoxantrone hydrochloride liposome for the treatment of breast cancer, the use of the above-mentioned liposome to obtain a drug for the treatment of breast cancer, as well as a method for treating breast cancer, including the introduction of the above-mentioned liposome. Use of mitoxantrone hydrochloride liposome for the preparation of a drug for the treatment of breast cancer, where the breast cancer is advanced recurrent or metastatic breast cancer that is unsuitable or resistant to endocrine therapy, HER2-negative or refractory to HER2-targeted therapy. A method for treating breast cancer, comprising administering to a patient with breast cancer a therapeutically effective amount of mitoxantrone hydrochloride liposome alone, wherein the breast cancer is advanced recurrent or metastatic breast cancer that is unsuitable or resistant to endocrine therapy, HER2-negative, or refractory to HER2-targeted therapy. Use of mitoxantrone hydrochloride liposome for the treatment of breast cancer in a patient where the breast cancer is advanced recurrent or metastatic breast cancer that is unsuitable or resistant to endocrine therapy, HER2-negative, or refractory to HER2-targeted therapy.

EFFECT: treatment of advanced recurrent or metastatic breast cancer, in which endocrine therapy and targeted anti-HER2 therapy are ineffective.

11 cl, 7 tbl, 1 ex